Clinical and laboratory management of the prothrombin G20210A mutation

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 11, 2002, Pages 1319-1325

  McGlennen, Ronald C ^a,b   Key, Nigel S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MMC Box 609 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ESTROGEN; PROTHROMBIN;

CONFERENCE PAPER; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LABORATORY TEST; MEDICAL LITERATURE; MEDICAL SOCIETY; MOLECULAR GENETICS; ONSET AGE; PATHOLOGIST; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREGNANCY; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA;

ADULT; BLOOD COAGULATION TESTS; COAGULATION PROTEIN DISORDERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MIDDLE AGED; MUTATION; PRACTICE GUIDELINES; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTHROMBIN; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0036881490     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (69)

1. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
2. Zivelin A, Rosenberg N, Faier S, et al. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood. 1998;92:1119-1124.
3. Dilley A, Austin H, Hooper WC, et al. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med. 1998;132:452-455.
4. Soria JM, Almasy L, Souto JC, et al. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood. 2000;95:2780-2785.
5. Gehring NH, Frede U, Neu-Yilik G, et al. Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet. 2001;28:389-392.
6. Butenas S, van't Veer C, Mann KG, "Normal" thrombin generation. Blood. 1999;94:2169-2178.
7. Kyrle PA, Mannhalter C, Beguin S, et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol. 1998;18:1287-1291.
8. Smirnov MD, Safa O, Esmon NL, Esmon CT. Inhibition of activated protein C anticoagulant activity by prothrombin. Blood. 1999;94:3839-3846.
9. Girolami A, Simioni P, Scarano L, Carraro G. Prothrombin and the prothrombin 20210 G to A polymorphism: their relationship with hypercoagulability and thrombosis. Blood Rev. 1999;13:205-210.
10. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 1999;99:999-1004.
11. Girolami A, Simioni P, Girolami B, Scarano L. G to A 20210 prothrombin polymorphism and venous thrombosis: simple association or causal relationship? Clin Appl Thromb Hemost. 2000;6:135-138.
12. Zoller B, Svensson PJ, Dahlback B, Hillarp A. The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families. Blood. 1998;91:2210-2211.
13. Salomon O, Steinberg DM, Zivelin A, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol. 1999;19:511-518.
14. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of Factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Thromb Haemost. 2001;86:809-816.
15. De Stefano V, Zappacosta B, Persichilli S, et al. Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. Br J Haematol. 1999;106:564-568.
16. Tosetto A, Rodeghiero F, Martinelli I, et al. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation. Br J Haematol. 1998;103:871-876.
17. Alhenc-Gelas M, Le Cam-Duchez V, Emmerich J, et al. The A20210 allele of the prothrombin gene is not frequently associated with the factor V Arg 506 to Gln mutation in thrombophilic families [letter]. Blood. 1997;90:1711.
18. Brown K, Luddinton R, Baglin T. Effect of the MTHFRC677T variant on risk of venous thromboembolism interaction with factor V Leiden and prothrombin (F2G20210A) mutations. Br J Haematol. 1998;103:42-44.
19. Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophiiia. Thromb Haemost. 1997;78:1426-1429.
20. Bovill EG, Hasstedt SJ, Callas PW, et al. The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred. Thromb Haemost. 2000;83:366-370.
21. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344:1527-1535.
22. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol. 1999;19:700-703.
23. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1840-1841.
24. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160:49-52.
25. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78:1183-1188.
26. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium [see comments]. N Engl J Med. 2000;342:374-380.
27. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet. 1999;353:1258-1265.
28. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340:9-13.
29. Kupferminc MJ, Peri H, Zwang E, Yaron Y, Wolman I, Eldor A. High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. Acta Obstet Gynecol Scand. 2000;79:963-967.
30. Martinelli I, Taioli E, Cetin I, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med. 2000;343:1015-1018.
31. Martinelli P, Grandone E, Colaizzo D, et al. Familial thrombophilia and the occurrence of fetal growth restriction. Haematologica. 2001;86:428-431.
32. Daly E, Vessey MP, Painter R, Hawkins MM. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet. 1996;348:1027.
33. Jick H, Jick SS, Myers MW, Vasilakis C. Third-generation oral contraceptives and venous thrombosis. Lancet. 1997;349:731-732; discussion 732-733.
34. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983-987.
35. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormonetherapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132:689-696.
36. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease [review]. Thromb Haemost. 2001;85:584-595.
37. Rosendaal FR, Siscovick DS, Schwartz SM, et al. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90:1747-1750.
38. Franco RF, Trip MD, ten Cate H, et al. The 20210 G→A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol. 1999;104:50-54.
39. Eikelboom JW, Baker RI, Parsons R, Taylor RR, van Bockxmeer FM. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease. Thromb Haemost. 1998;80:878-880.
40. Corral J, Gonzalez-Conejero R, Lozano ML, Rivera J, Heras I, Vicente V. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol. 1997;99:304-307.
41. Ferraresi P, Marchetti G, Legnani C, et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol. 1997;17:2418-2422.
42. Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women, JAMA. 2001;285:906-913.
43. Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Lang JE. Interaction of estrogen replacement therapy with the thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic vascular disease: a cross-sectional study of 275 hyperlipidemic women. Metabolism. 2001;50:360-365.
44. Poort SR, Bertina RM, Vos HL. Rapid detection of the prothrombin 20210 A variation by allele specific PCR. Thromb Haemost. 1997;78:1157-1158.
45. Mitterer M, Lanthaler AJ, Mair W, Giacomuzzi K, Coser P. Simultaneous detection of FV Q506 and prothrombin 20210 A variation by allele-specific PCR. Haematologica. 1999;84:204-207.
46. Maher C, Crowley D, Cullen C, Wall C, Royston D, Fanning S. Double fluorescent-amplification refractory mutation detection (dF-ARMS) of the factor V Leiden and prothrombin mutations. Thromb Haemost. 1999;81:76-80.
47. Del Rio-LaFreniere SA, Olson DJ, McGlennen RC. Modified molecular based Factor V Leiden testing: use of the unique simultaneous allele specific amplification (SASA) assay and FTA paper for cost effective genotyping. Mol Diagn. 2001;6:201-209.
48. Huber S, McMaster KJ, Voelkerding KV. Analytical evaluation of primer engineered multiplex polymerase chain reaction-restriction fragment length polymorphism for detection of factor V Leiden and prothrombin G20210A. J Mol Diagn. 2000;2:153-157.
49. Benson JM, Ellingsen D, Renshaw MA, Resler AG, Evatt BL, Hooper WC. Multiplex analysis of mutations in four genes using fluorescence scanning technology. Thromb Res. 1999;96:57-64.
50. von Ahsen N, Schutz E, Armstrong VW, Oellerich M. Rapid detection of prothrombotic mutations of prothrombin (G20210A), factor V (G1691A), and methylenetetrahydrofolate reductase (C677T) by real-time fluorescence PCR with the LightCycler. Clin Chem. 1999;45:694-696.
51. Parks SB, Popovich BW, Press RD. Real-time polymerase chain reaction with fluorescent hybridization probes for the detection of prevalent mutations causing common thrombophilic and iron overload phenotypes. Am J Clin Pathol. 2001;115:439-447.
52. Kwiatkowski RW, Lyamichev V, de Arruda M, Neri B, Clinical, genetic, and pharmacogenetic applications of the invader assay. Mol Diagn. 1999;4:353-364.
53. Gomez E, van der Poel SC, Jansen JH, van der Reijden BA, Lowenberg B. Rapid simultaneous screening of factor V Leiden and G20210A prothrombin variant by multiplex polymerase chain reaction on whole blood [letter] [see comments]. Blood. 1998;91:2208-2209.
54. Hezard N, Cornillet-Lefebvre P, Gillot L, Potron G, Nguyen P. Multiplex ASA PCR for a simultaneous determination of factor V Leiden gene, G→A 20210 prothrombin gene and C→T 677 MTHFR gene mutations [letter]. Thromb Haemost. 1998;79:1054-1055.
55. Leyte A, Smits PH, van Straalen JP, van Doom LJ, Quint WG. Automated, simultaneous detection of the factor V Leiden and prothrombin (G20210A) variants using multiplex PCR and a line probe assay. Thromb Haemost. 2000;83:354-355.
56. Endler G, Kyrle PA, Eichinger S, Exner M, Mannhalter C. Multiplexed mutagenically separated PCR: simultaneous single-tube detection of the factor V R506Q (G1691A), the prothrombin G20210A, and the methylenetetrahydrofolate reductase A223V (C677T) variants. Clin Chem. 2001;47:333-335.
57. Wisotzkey JD, Bell T, Monk JS. Simultaneous polymerase chain reaction restriction fragment length polymorphism identification of the factor V Leiden allele and the prothrombin 20210A mutation. Diagn Mol Pathol. 1998;7:180-183.
58. Nauck M, Marz W, Wieland H. Evaluation of the Roche diagnostics LightCycler-Factor V Leiden Mutation Detection Kit and the LightCycler-Prothrombin Mutation Detection Kit. Clin Biochem. 2000;33:213-216.
59. van den Bergh FA, van Oeveren-Dybicz AM, Bon MA. Rapid single-tube genotyping of the factor V Leiden and prothrombin mutations by real-time PCR using dual-color detection. Clin Chem. 2000;46:1191-1195.
60. Cheung VG, Morley M, Aguilar F, Massimi A, Kucherlapati R, Childs G. Making and reading microarrays. Nat Genet. 1999;21:15-19.
61. Witowski NE, Leiendecker-Foster C, Gerry NP, Mc-Glennen RC, Barany G. Microarray-based detection of select cardiovascular disease markers. Biotechniques. 2000;29:936-939.
62. Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol. 2000;111:1223-1229.
63. Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81:14-17.
64. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.
65. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol. 2001;113:630-635.
66. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999;341:801-806.
67. Margaglione M, D'Andrea G, Colaizzo D, et al. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost. 1999;82:1583-1587.
68. Brenner B, Hoffman R, Blumenfeld Z, Welner Z, Younis JS. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000;83:693-697.
69. Olson JD. College of American Pathologists Consensus Conference XXXVI: Diagnostic Issues in Thrombophilia: introduction and general considerations. Arch Pathol Lab Med. 2002;126:1277-1280.